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Whereas most calpains are cytosolic proteases, calpain 10 is
resident in mitochondria and is important in mitochondrial
homeostasis. Because calpain 10 has been implicated in type
2 diabetes, we studied its possible role in diabetes-induced
renal dysfunction. We treated renal proximal tubular
cells with high glucose (17mmol/l) and found decreased
mitochondrial calpain 10 mRNA and protein at 96h
compared with cells incubated with 0 or 5mmol/l glucose or
17mmol/l D-mannitol. High glucose increased mitochondrial
calpain 10 substrates (NDUFB8 and ATP synthase b),
decreased basal and uncoupled respiration, and initiated cell
apoptosis as indicated by cleaved caspase 3 and nuclear
condensation. Renal calpain 10 protein and mRNA were
specifically decreased in streptozotocin-induced diabetic
rats with kidney dysfunction, and in diabetic ob/ob mice.
In agreement with our in vitro data, the kidneys of
streptozotocin-induced diabetic rats had elevated calpain
10 substrates and cleaved caspase 3. Finally, specific siRNA-
induced knockdown of calpain 10 in the proximal tubules of
control rats resulted in decreased renal function as evidenced
by increased serum creatinine, and increased caspase 3
cleavage compared with rats receiving scrambled siRNA.
Thus, the glucose-induced loss of calpain 10 in vivo results in
renal cell apoptosis and organ failure through accumulation
of mitochondrial calpain 10 substrates and mitochondrial
dysfunction. Whether this is a major cause of the decreased
renal function in diabetic nephropathy will require further
studies.
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The most prevalent cause of chronic renal failure and
end-stage renal disease is diabetic nephropathy—previously
described as a glomerulopathy associated with diffuse or
nodular glomerulosclerosis—although fewer than one-third
of diabetic patients have this type of glomerulopathy.1,2
Proximal tubular functional and structural changes correlate
better with diabetic nephropathy progression, and may
be key to kidney dysfunction development in diabetes.3,4
Disruption of mitochondrial function is important in
various diseases including diabetes, and diabetes induced
in rats by streptozotocin (STZ) or alloxan treatment results in
impaired mitochondrial respiration and disruption of energy
production and mitochondrial protein synthesis in the
kidney.5–8 Ultimately, changes in mitochondrial viability
lead to cell death via apoptosis or necrosis, but the exact
mechanism of mitochondrial dysfunction in diabetic
nephropathy is unclear.
Calpain 10 is a ubiquitously expressed ‘atypical’ calpain.9,10
Calpain 10 gained much attention following a genome-wide
linkage scan for susceptibility genes associated with dia-
betes.11,12 Since calpain 10 was identified as a type 2 diabetes
susceptibility gene in 2000, there have been numerous reports
supporting and refuting this proposed association.11,13 Never-
theless, calpain 10 has been implicated in both insulin-
stimulated glucose uptake14,15 and insulin secretion16,17 in
islet cells.
Whereas calpains were traditionally thought to be
cytosolic proteases, our laboratory identified calpain 10 as
the resident mitochondrial calpain in isolated rabbit, mouse,
and rat renal mitochondria with primary activity in the
matrix.18,19 In addition, calpain 10 was shown to be a
mediator of Ca2þ -induced mitochondrial dysfunction
through cleavage of complex I subunits, NDUFV2 and
NDUFB8, of the electron transport chain.18 Interestingly,
overexpression of calpain 10 in NIH-3T3 cells resulted in
mitochondrial swelling, autophagy, and cell death,18 suggest-
ing that calpain 10 is important in mitochondrial homeo-
stasis. In contrast, knockdown of calpain 10 protein
expression resulted in renal proximal tubular cell (RPTC)
apoptosis,20 illustrating the double-edged sword of calpain 10.
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We also observed a decrease in renal calpain 10 protein and
mRNA expression in aged humans, mice, and rats that was
attenuated with caloric restriction and correlated with
decreased kidney function in rats.20 These studies provide
evidence that renal calpain 10 is important in age-related loss
of renal function. The goal of this study was to determine the
role of calpain 10 in renal dysfunction observed in diabetes
using two different animal models of diabetes: an RPTC
in vitro model and an in vivo rat kidney model after calpain 10
knockdown.
RESULTS
Elevated glucose biphasically regulates mitochondrial
calpain 10 in RPTCs
To investigate the effects of elevated glucose on calpain
protein expression over time, RPTCs were treated with
17 mmol/l glucose for 3–144 h. Physiological glucose is
B5 mmol/l; 17 mmol/l is commonly used to simulate
elevated glucose.21 Cytosolic calpain 1 or 2 protein content
did not change at any time (Figure 1a). Cytosolic calpain 10
protein content did not change until 120 h (decreased 46%).
In contrast, mitochondrial calpain 10 protein increased
after 3, 6, and 12 h of 17 mmol/l glucose exposure, returned
to control at 24 and 48 h, and then markedly decreased at
72, 96, and 120 h (Figure 1a). Calpains 1 and 2 are not
present in mitochondria of RPTCs.18 Of note, control RPTCs
incubated in 5 mmol/l glucose, 11 mmol/l glucose, 11 mmol/l
D-mannitol, or 17 mmol/l D-mannitol had no effect on
calpain 10 protein expression at any time (Figure 1b and
Supplementary Figure S1 online). These data reveal that
glucose elevated threefold, but not twofold, regulates mito-
chondrial calpain 10 protein expression in RPTCs biphasically,
with increasing expression at early times (3–12 h) and
depleting mitochondrial calpain 10 at 3 days and beyond.
To document that the gain/loss of mitochondrial calpain 10
protein from elevated glucose exposure changed mitochondrial
calpain 10 activity, RPTCs were treated as described above,
mitochondrial and cytoplasmic fractions isolated, and calpain
activity was examined using succinyl-Leu-Leu-Val-Tyr-7-ami-
no-4-methylcoumarin. RPTCs treated with 17 mmol/l glucose
underwent no cytoplasmic calpain activity changes at any point
in time (data not shown). However, mitochondrial calpain
activity increased at 6 and 12 h of 17 mmol/l glucose treatment
and decreased at 4 days (Figure 1c). The calpain inhibitor
calpeptin inhibited mitochondrial calpain activity, providing
evidence that the succinyl-leu-leu-val-tyr-7-amino-4-methyl-
coumarin hydrolysis reflects calpain activity (Figure 1c).
Mitochondrial calpain activity did not change with 5 mmol/l
glucose or 17 mmol/l D-mannitol at any time (Figure 1d). The
data confirm that elevated glucose regulates mitochondrial
calpain 10 protein and activity in a biphasic manner.
Calpain 10 mRNA expression in RPTCs is decreased
specifically by chronic elevated glucose
Because chronic elevated glucose decreased calpain 10
protein in RPTCs, we examined calpain 10 mRNA expression
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Figure 1 |Calpain protein expression in glucose-treated renal proximal tubular cells (RPTCs). (a) RPTCs were incubated in 5mmol/l
(Con) or 17mmol/l for various times, mitochondrial and cytoplasmic fractions isolated, and immunoblot analysis performed. b-Actin and
heat shock protein 60 (HSP60) were used as loading controls. Results were reproduced in four different experiments. (b) RPTCs incubated
were in 17mmol/l D-mannitol over time and calpain 10 was measured in cytosol and mitochondria. (c) Mitochondrial calpain 10 activity was
measured in RPTC mitochondria over time. Calpeptin, a calpain inhibitor, was used to verify calpain activity. (d) RPTCs were incubated with
17mmol/l D-mannitol, 17mmol/l glucose, or 5mmol/l glucose over time and mitochondrial calpain activity determined. Data are
means±s.e.m., NX4. þSignificantly different from control; *Significantly different from time-matched sample (Pp0.05). SLLVY-AMC,
succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin.
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to determine if this decrease was transcriptionally regulated.
Calpain 1 mRNA expression did not change at any time in
17 mmol/l glucose-treated RPTCs (Figure 2). However, cal-
pain 10 mRNA expression decreased, but only after 4 days of
elevated glucose exposure (Figure 2, data not shown),
correlating with the decrease in calpain 10 protein and
activity. No change in calpain 10 mRNA occurred in cells
incubated with 17 mmol/l D-mannitol. Thus, prolonged
incubation with elevated glucose transcriptionally down-
regulates calpain 10 in RPTCs.
Mitochondrial function is decreased in RPTCs exposed to
chronic elevated glucose
Because chronic elevated glucose caused loss of mito-
chondrial calpain 10 expression, RPTCs were treated with
17 mmol/l glucose and RPTC respiration was measured at
different times. There was no change in basal respiration until
4 days of glucose treatment at which time it decreased 50%
(Figure 3a). After basal respiration was determined, FCCP
(carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) was
added to obtain uncoupled QO2, which is used here as a
stress test to ascertain underlying defects in the electron
transport chain when maximally stimulated. Uncoupled
respiration remained constant until 4 days of glucose
treatment at which time it decreased 50% (Figure 3b). Basal
or uncoupled respiration did not change at any time in
RPTCs treated with 17 mmol/l D-mannitol (Figure 3a and b).
Therefore, prolonged exposure to elevated glucose causes
mitochondrial dysfunction in RPTCs.
Prolonged exposure to glucose elevates protein expression
of NDUFB8 and ATP synthase b
We previously reported that electron transport chain protein
NDUFB8 and adenosine triphosphate (ATP) synthase b are
substrates for mitochondrial calpain 10.18 Because 17 mmol/l
glucose decreased mitochondrial calpain 10 expression, we
hypothesized that mitochondrial calpain 10 substrates may
increase. With immunoblot, we noted no change in NDUFB8
or ATP synthase b protein expression in 17 mmol/l glucose-
treated RPTCs at 6 or 24 h (Figure 4a). However, both
proteins increased after 96 h of glucose treatment. Accumula-
tion of NDUFB8 and ATP synthase b correlates with the loss
of mitochondrial calpain 10 at 96 h. There was no change
in NDUFB8 or ATP synthase b in RPTCs treated with
17 mmol/l D-mannitol (Figure 4b). In addition, mRNA of
NDUFB8 or ATP synthase b did not change, suggesting that
increases in these proteins are not because of increased
transcription under these conditions (Figure 4c and d).
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Figure 2 |Calpain mRNA expression in glucose-treated renal
proximal tubular cells (RPTCs). RPTCs were incubated in
17mmol/l glucose or 17mmol/l D-mannitol over time. Cells were
collected, mRNA was isolated, and reverse transcriptase-PCR
(RT-PCR) was performed using calpain 10, calpain 1, and b-actin
primers. Data are means±s.e.m., NX4. *Significantly different
from D-mannitol (Pp0.05).
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Figure 3 |Mitochondrial respiration in glucose-treated renal
proximal tubular cells (RPTCs). RPTCs were incubated in
17mmol/l glucose or 17mmol/l D-mannitol over time. Cells were
collected and (a) basal and (b) uncoupled respiration was
measured. Uncoupled respiration was measured in the presence
of 10mmol/l carbonyl cyanide-p-trifluoromethoxyphenylhydra-
zone (FCCP). Data are means±s.e.m. (N¼ 4). *Significantly
different from D-mannitol (Pp0.05).
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Chronic elevated glucose causes RPTC apoptosis
We previously showed that ‘knockdown’ of mitochondrial
calpain 10 caused RPTC apoptosis.20 To investigate the effects
of chronic elevated glucose on RPTC apoptosis, we examined
nuclear condensation and caspase 3 activation. Examination
of nuclear morphology using 4,6-diamidino-2-phenylindole
staining revealed normal nuclei (495%) in controls and
at 6 h of 17 mmol/l glucose treatment (Figure 5a and b).
However, at 96 h of glucose treatment, RPTCs contained
B30% condensed nuclei. Using immunoblot analysis,
we observed cleaved procaspase 3 in RPTCs treated with
17 mmol/l glucose for 96 h (Figure 5c). No cleaved procas-
pase 3 was observed in control and RPTCs treated with
glucose for 6 h (Figure 5c). Thus, loss of calpain 10 by
chronic elevated glucose causes RPTC apoptosis.
Renal calpain 10 protein expression is depleted in
STZ-induced diabetic rats and diabetic ob/ob mice
Our RPTC data revealed that chronic elevated glucose
decreased calpain 10 expression, and hence we next measured
calpain expression in two in vivo rodent diabetes models. At
10 weeks after induction of STZ-induced diabetes in the rat,
serum glucose was 408±30 mg/dl and serum creatinine was
2.8±0.5 mg/dl. In contrast, control, vehicle-treated animals
had serum glucose of 128±17 mg/dl and serum creatinine of
0.5±0.1 mg/dl. Thus, this diabetic rat model has increased
serum glucose and decreased kidney function at 10 weeks.
Compared with controls, renal calpain 1 or 2 protein
expression did not change in STZ-treated rats (Figure 6a). In
contrast, calpain 10 protein expression decreased in STZ-
induced rats, suggesting that the effect of diabetes was unique
to calpain 10. Compared with controls, calpain 10 mRNA was
also decreased, suggesting that calpain 10 is transcriptionally
downregulated in STZ-induced diabetic kidneys (Figure 6b).
Calpain 1 mRNA did not change, correlating with the lack of
change in calpain 1 protein expression (Figure 6b).
We also measured renal calpain 10 in another in vivo
model of diabetes, the ob/ob mouse. We obtained blood and
kidney samples from both control and ob/ob 8-week-old
male mice. The average blood glucose in the ob/ob mice was
400±31 mg/dl and 204±29 mg/dl in lean mice. There was a
decrease in renal calpain 10 protein expression in the diabetic
ob/ob mice compared with the control but no change in
calpain 1 protein expression (Figure 6c). These results reveal
that calpain 10 is specifically decreased in two in vivo models
of diabetes. Importantly, in the STZ model, we observed a
decrease in renal calpain 10 protein and mRNA expression
that correlates with decreased renal function. In addition,
renal calpain 10 is transcriptionally downregulated in STZ-
induced diabetic rats.
NDUFB8 and ATP synthase b protein expression and
apoptosis increase in STZ-induced diabetic kidneys
Because we observed increases in the calpain 10 substrates
NDUFB8 and ATP synthase b in RPTCs treated chronically
with elevated glucose, we examined the expression of these
proteins in STZ-induced diabetic kidneys. Compared with
controls, there was an increase in both NDUFB8 and ATP
synthase b protein expression in the STZ-induced diabetic
kidney, correlating with our in vitro data (Figure 7a and b).
In addition, cleaved procaspase 3 and increased terminal
deoxynucleotidyl transferase dUTP nick end labeling
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Figure 4 |NDUFB8 and adenosine triphosphate (ATP) synthase b protein expression in glucose-treated renal proximal tubular cells
(RPTCs). RPTCs were incubated in (a) 17mmol/l glucose or (b) 17mmol/l D-mannitol over time. Cell lysates were subjected to immunoblot
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(TUNEL) staining were observed in the STZ-induced
diabetic kidney, providing evidence that STZ-induced
diabetes is causing renal apoptosis (Figure 7a–c). There was
no change in mRNA expression of NDUFB8 and ATP
synthase b (Figure 7d), correlating with our in vitro data
and providing evidence that the increase in NDUFB8 and
ATP synthase b is not due to increased synthesis.
In vivo siRNA knockdown of renal calpain 10
To determine whether decreased calpain 10 is sufficient to
induce renal dysfunction, rats were treated with calpain
10 small interfering RNA (siRNA) to decrease renal calpain
10. This effective approach has been used by many
investigators because siRNA accumulates in the renal
proximal tubule and decreases its target protein.22–26 Rats
were treated with siRNA (20 nmol) directed against calpain
10 or scrambled siRNA by tail vein injection. Tissues were
isolated, homogenized, and immunoblot analysis performed.
A single intravenous dose of a siRNA directed against calpain
10, but not that of a negative siRNA (scrambled), decreased
calpain 10 protein and mRNA expression in rat kidney cortex
(Figure 8a). The siRNA directed against calpain 10 had no
effect on calpain 1 in kidney cortex or calpain 10 in the liver
(Supplementary Figure S2 online). Therefore, we have an
in vivo model of renal-specific calpain 10 knockdown to
examine the functional consequences thereof.
To examine the effects of calpain 10 loss in rat kidneys, we
measured serum creatinine, cleavage of caspase 3, and
TUNEL staining. In rats treated with the calpain 10 siRNA,
there was an increase in serum creatinine to 1.7±0.2 mg/dl
at 7 days (Figure 8b). The serum creatinine for negative
siRNA was 0.7±0.1 mg/dl and did not change over time.
These data suggest that the loss of renal calpain 10 causes
renal dysfunction. In addition, immunoblots of caspase
3 showed activation of caspase 3 after 5 and 7 days of calpain
10 siRNA but not in negative siRNA-treated rat kidneys
(Figure 8c). There was also an increase in TUNEL-positive
cells in the calpain 10 siRNA-treated kidney (Figure 8d).
We suggest that the loss of calpain 10 in vivo results in renal
apoptosis and renal dysfunction.
DISCUSSION
Our data reveal that diabetic glucose specifically decreases
mitochondrial calpain 10 expression in RPTCs and that renal
calpain 10 is decreased in diabetic rats and mice. Further-
more, the loss of renal calpain 10 resulted in apoptosis
in vitro and in vivo, and decreased renal function in the rat.
We suggest that the loss of calpain 10 is key in diabetes-
induced renal dysfunction and, ultimately, diabetic nephrop-
athy. These data complement our previous work in which
we reported that mitochondrial calpain 10 is required for cell
viability, and calpain 10 specifically decreases in aging rat,
mouse, and human kidney tissues when renal function
decreases.20 We provide evidence that calpain 10 is required
for renal function and contributes to two common renal
diseases. Finally, calpain 10 is ubiquitously expressed and
our findings have broader implications in other tissues
and diseases.
Examining the effect of elevated glucose on calpain
expression over time, we observed an acute increase in
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calpain 10 protein and activity between 3 and 12 h after
17 mmol/l glucose exposure that returned to control at 24 h.
Increased calpain 10 was not due to increased transcription
and we propose that increased calpain 10 is due to decreased
degradation. Finally, the rapid increase in calpain 10 by glucose
suggests that renal mitochondrial calpain 10 is important in
renal metabolism and is regulated by nutrients.
It is noteworthy that the acute and chronic effects of
glucose act specifically on mitochondrial calpain 10; two
calpain family members (calpains 1 and 2) did not change
over time. In contrast, the decrease in calpain 10 protein and
activity in RPTCs after 3–5 days of 17 mmol/l glucose
treatment was associated with a decrease in calpain 10
mRNA, suggesting glucose induced a decrease in calpain
10 transcription. A mechanism for decreased calpain 10
transcription by glucose has not been reported.
The decrease in mitochondrial calpain 10 protein occurred
before a decrease in cytoplasmic calpain 10. We reported
similar results when calpain 10 was ‘knocked down’ with
short hairpin RNA20 and suggest that mitochondrial calpain
10 turnover is greater than cytosolic calpain 10.
The decrease in RPTC calpain activity observed during
chronic glucose exposure also has been reported in other
cellular models. Diaz-Villasenor et al.27 reported a decrease in
calpain activity in lymphocytes from diabetic patients. The
increase in RPTC calpain activity by short-term glucose also
has been reported to occur in cardiomyocytes,28 but the
calpain isoform that was being measured was not identified.
Given that calpain 10 is a protease, decreased calpain
10 expression may result in the accumulation of its
substrates. There was no change in NDUFB8 and ATP
synthase b after acute glucose treatment of RPTCs, but
chronic glucose-induced RPTC mitochondrial calpain 10 loss
resulted in increased NDUFB8 and ATP synthase b. We also
explored this possibility in the rat STZ diabetic model and
observed that renal NDUFB8 and ATP synthase b increased
in concert with the loss of renal calpain 10. Thus, we
hypothesize that the initiating mitotoxic event induced by the
loss of mitochondrial calpain 10 is the accumulation of
mitochondrial calpain 10 substrates. Supporting our hypoth-
esis, we observed that chronic glucose treatment decreased
RPTC basal and uncoupled RPTC respiration, markers
of mitochondrial dysfunction. We observed no changes in
mitochondrial function at earlier times of glucose treatment
(that is, 12, 24, and 48 h).
We previously reported that knockdown of calpain 10
with short hairpin RNA resulted in RPTC apoptosis.20 We
observed apoptosis at 96 h after glucose treatment, when
calpain 10 was decreased, but not at 6 h. We also explored this
possibility in the rat STZ diabetic model and observed
caspase 3 cleavage in concert with the loss of renal calpain 10.
Importantly, we show the loss of renal calpain 10 by siRNA
in vivo results in activation of caspase 3 in the kidney
cortex. These results combined with the results from our
earlier study20 provide evidence that the accumulation of
mitochondrial proteins and mitochondrial dysfunction
2.5
2
1
1.5
0.5
0
5 Days 7 Days
Calpain 10 siRNA
*
*
Negative siRNA
Se
ru
m
 c
re
a
tin
in
e 
(m
g/d
l)
2 Days
Days of siRNA treatment
Kidney cortex
Neg siRNA
a
c
d
b
Neg siRNA
Neg siRNA
Cal 10 siRNA
Cal 10 siRNA
Cal 10 siRNA
Calpain 10
Calpain 1
36 kDa
45
40
35
30
25
20
15
10
0
5TU
NE
L-
po
sit
ive
 c
e
lls
17 kDa
42 kDa
Cleaved
caspase 3
Caspase 3
Calpain 10
Day 2 2 5 7 7
75 kDa
42 kDa
5
Day 2 2 5 7 75
GAPDH
GAPDH
GAPDH
Kidney cortex mRNA
+ +
+
+
+ +
–––
– – –
+ +
+
+
+ +
–––
– – –
Neg siRNA
Cal 10 siRNA
Day 2 2 5 7 75
+ +
+
+
+ +
–––
– – –
Figure 8 | The effect of small interfering RNA (siRNA) on calpain protein in rat kidney. Eight-week-old rats were treated with 20 nmol of
siRNA directed against calpain 10 (Cal 10) or a scrambled siRNA (Neg) by tail vein injection. (a) Kidney cortex was isolated and calpain
10 protein was measured by immunoblot analysis. Calpain 10 and 1 mRNA was measured by reverse transcriptase-PCR (RT-PCR).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control. (b) Blood was collected from rats and serum creatinine was
determined. (c) Kidney cortex was isolated and procaspase 3 and cleaved caspase 3 (17 kDa) protein was measured by immunoblot analysis.
GAPDH served as a loading control. (d) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells were determined.
Results were reproduced in at least four different animals. Data are means±s.e.m., NX4. *Significantly different from control (Po0.05).
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associated with the loss of renal calpain 10 lead to apoptosis
in vitro and in vivo.
In an earlier study, 25 mmol/l glucose for 6 and 24 h produced
necrotic cell death in LLC-PK cells.29 However, we observed no
RPTC death at 6 or 24 h. These results could be due to different
glucose concentrations used but, more likely, the difference arises
from the use of an immortalized cell line and our use of primary
cultures cultured under aerobic conditions.30,31
STZ-induced diabetic rats had elevated glucose and
increased serum creatinine after 10 weeks. As we observed
in RPTCs, renal calpain 10 mRNA and protein were
decreased and calpains 1 and 2 were not, suggesting that
decreases in renal calpain 10 observed in diabetes is because
of decreased calpain 10 transcription. We conducted a similar
experiment in the diabetic ob/ob mouse and observed that
with elevated glucose, renal function decreased, suggesting
that calpain 10 decreases with elevated glucose in multiple
animal models.
We developed an in vivo model of renal calpain 10
knockdown using siRNA. This effective approach has been
used by a number of investigators: siRNA accumulates in the
renal proximal tubule and decreases its target protein.22–26
The loss of both protein and mRNA expression of calpain
10 in the kidney cortex results in kidney dysfunction. Caspase
3 activation increased, suggesting that the loss of calpain
10 in vivo results in apoptosis. These data provide strong
evidence that the loss of renal calpain 10 is sufficient to
induce kidney injury.
In summary, renal calpain 10 protein and mRNA decrease
with chronic elevated glucose, both in vitro and in vivo, a
decrease that correlates with increased calpain 10 substrates
resulting in mitochondrial dysfunction and apoptosis. Loss
of renal calpain 10 by siRNA in vivo results in renal
dysfunction and apoptosis, suggesting a direct relationship
between loss of calpain 10 protein expression and renal
dysfunction. These data collectively indicate that the loss of
calpain 10 in vivo results in renal apoptosis and renal
dysfunction, underscoring that the loss of calpain 10 causes
mitochondrial dysfunction leading to cell death in diabetic
nephropathy.
MATERIALS AND METHODS
Renal proximal tubules
Isolation and culture of renal proximal tubules were performed as
described previously.30,31 RPTCs were isolated from female New
Zealand White rabbits (1.5–2.5 kg) using the iron oxide perfusion
method and grown under improved conditions. The advantage of
this model is that RPTCs cultured under these conditions exhibit
greater differentiated function, an in vivo–like rate of oxidative
metabolism, and limited glycolysis and are gluconeogenic.30,31
Mitochondrial isolation and fractionation
RPTC mitochondria were isolated via differential centrifugation as
previously described.18 Mitochondrial purity was determined by
measuring the levels of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and heat shock protein 60 (HSP60) in the cytosol and
mitochondria (Supplementary Figure S3 online).
Immunoblot analysis
Rat and mouse kidney tissue, and RPTCs were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes. Membranes were incubated with primary
antibodies to calpains 1, 2, and 10, and HSP60 (used to normalize
mitochondrial fractions), or GAPDH. The primary antibodies used
were m-calpain (domain IV) (Calbiochem, La Jolla, CA; 1:1000),
m-calpain (domains III and IV) (Abcam, Cambridge, MA; 1:1000),
calpain 10 (Abcam; 1:1000), caspase 3 (StressGene, San Diego, CA;
1:1000), HSP60 (Abcam; 1:1000), ATP Synthase b (1:1000), NDUFB8
(Invitrogen, Carlsbad, CA; 1:1000), and GAPDH (Fitzgerald Anti-
bodies, Acton, MA; 1:1000). We previously reported that ND6 was
a substrate for calpain 10.18 The anti-ND6 antibody (Invitrogen)
manufacturer recently informed us that the antibody actually
identifies the mitochondrial complex 1 protein NDUFB8. Thus,
NDUFB8 is a substrate of mitochondrial calpain 10. Antibody
incubation was followed by a horseradish peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibody (Santa Cruz, Santa Cruz,
CA; 1:1000). Immunoreactive protein was visualized by enhanced
chemiluminescence (Amersham, GE Healthcare, Piscataway, NJ) and
imaged using an Alpha Innotech imaging station (Santa Clara, CA).
STZ diabetic model
Male Sprague–Dawley rats, 8 weeks of age (200–250 g), were starved for
16 h and injected once with STZ (55 mg/kg, tail vein) in sodium citrate
buffer.32–34 Afterward, rats were given drinking water supplemented
with sucrose (15 g/l) for 48 h to limit mortality as stores of insulin are
released from damaged pancreatic islets. Aged matched males rats were
controls. After 24 h, diabetes was confirmed in STZ-treated rats by
measuring tail vein plasma glucose. At 10 weeks after diabetes
induction, rats were killed and blood and kidneys were harvested.
Ob/ob mice
For the ob/ob mice study, 8-week-old male ob/ob (leptin/) and
lean controls (Jackson Labs, Bar Harbor, Maine) were used. Mice
were killed and blood and kidneys were harvested. Kidneys were
homogenized and immunoblot analyses were performed.
Reverse transcription PCR
Rat kidney samples were homogenized with TRIZOL reagent
(Invitrogen) according to the manufacturer’s protocol to extract total
RNA. The mRNA was subjected to reverse transcription to DNA using
Moloney murine leukemia virus (MMLV) reverse transcriptase
(Invitrogen) in the presence of oligo dT primers. PCR was performed
using primers for calpains 1, 2, and 10, which has previously been
reported.15 Amplification of a-GAPDH was used as internal control
for normalizing PCR efficiency. Products were electrophoresed on
1.5% agarose gel and stained with ethidium bromide.
Calpain activity
Calpain activity was assayed spectrophotometrically using the
calpain substrate succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(Bachem, Torrance, CA) as previously described.18
TUNEL assay
The In Situ Cell Death Detection kit (Roche, Indianapolis, IN) was
used. After deparaffinization, the sections were treated with
proteinase K (20 g/ml) and kit protocol was followed. TUNEL-
positive cells were counted in 10 non-overlapping fields in each
section under  100 magnification.
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Measurement of RPTC oxygen consumption (QO2)
QO2 was monitored as previously described using a Clark-type
oxygen electrode.18 After the basal rate of QO2 was determined,
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (final con-
centration¼ 10 mmol/l) was injected to obtain uncoupled QO2.
Assessment of nuclear morphology
Nuclear morphology was assessed as previously described.35 Visua-
lization of 4,6-diamidino-2-phenylindole staining was performed
using a fluorescence microscope and condensed nuclei in 12 cells
from 10 high-powered fields were counted for each treatment group.
In vivo siRNA
In vivo siRNA was administered as previously described.26 Male
Sprague–Dawley rats, 6–8 weeks of age, were treated with calpain
10 siRNA (50-CCAGGACAUUUGUGCCACACCUCAA-30) (Invitro-
gen) or a negative control (scramble) (Invitrogen), with a phospho-
rothioate backbone that decreases degradation and extends its
effectiveness, in a sterile siRNA resuspension buffer (Invitrogen) to
decrease renal calpain 10. Rats were treated with 20 nmol of siRNA
directed against calpain 10 or scrambled siRNA by tail vein
injection. Tissues were isolated, homogenized, and immunoblot
performed. Serum creatinine measurements were performed with
the appropriate kit (Bioassay Systems, Hayward, CA).
Statistical analysis
RPTCs isolated from one rabbit represents one experiment (n¼ 1).
The appropriate analysis of variance was performed for each data
set using SigmaStat statistical software (Ashburn, VA). Individual
means were compared with Fisher’s protected least significant
difference test with Pp0.05 being considered statistically significant.
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